Joining Forces to Address Unanswered Questions - The European PEACE Consortium - Interview with Karim Fizazi
March 28, 2018
Karim Fizazi, MD, Ph.D. is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France and Professor of Oncology at the University of Paris. He received his medical degree in 1995 and completed a fellowship in 1997, both in medical oncology. He obtained a Ph.D. in Molecular Oncology in 2003.
Alicia Morgans, MD, MPH.
A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer (PEACE I)
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse (PEACE II)
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration-Resistant Prostate Cancer Patients Metastatic to Bone (PEACE III)